NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer’s Disease Biomarkers at AAIC 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 30 2025
0mins
Source: Globenewswire
Obicetrapib's Impact on Alzheimer's Biomarkers: The clinical trial results indicate that obicetrapib significantly reduced plasma levels of p-tau217, a key Alzheimer’s disease biomarker, particularly in ApoE4 carriers, suggesting its potential as a preventive treatment for Alzheimer's.
Cardiometabolic Benefits: In addition to its effects on Alzheimer's biomarkers, obicetrapib demonstrated favorable outcomes in lowering LDL cholesterol and other cardiometabolic risk factors, highlighting its dual therapeutic potential in addressing both cardiovascular and neurodegenerative diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
